Influence of control group design on outcome in recent antipsychotic clinical trials for schizophrenia

被引：0
|
作者：
Woods, SW [1 ]
Gueorguieva, RV [1 ]
Makuch, RW [1 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT 06519 USA
来源：
SCHIZOPHRENIA RESEARCH | 2002年 / 53卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [1] Control group bias in randomized atypical antipsychotic medication trials for schizophrenia
    Woods, SW
    Gueorguieva, RV
    Baker, CB
    Makuch, RW
    ARCHIVES OF GENERAL PSYCHIATRY, 2005, 62 (09) : 961 - 970
  • [2] Antipsychotic maintenance in schizophrenia: Partial compliance and clinical outcome
    Docherty, J
    Mahmoud, R
    Grogg, A
    Kozma, C
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 281 - 282
  • [3] Consistency of atypical antipsychotic superiority to placebo in recent clinical trials
    Woods, SW
    Stolar, M
    Sernyak, MJ
    Charney, DS
    BIOLOGICAL PSYCHIATRY, 2001, 49 (01) : 64 - 70
  • [4] Determinants of Antipsychotic Response in Schizophrenia: Implications for Practice and Future Clinical Trials
    Rabinowitz, Jonathan
    Werbeloff, Nomi
    Caers, Ivo
    Mandel, Francine S.
    Stauffer, Virginia
    Menard, Francois
    Kinon, Bruce J.
    Kapur, Shitij
    JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (04) : E308 - U33
  • [5] Design of control-group conditions in clinical trials of behavioral interventions
    Lindquist, Ruth
    Wyman, Jean F.
    Talley, Kristine M. C.
    Findorff, Mary J.
    Gross, Cynthia R.
    JOURNAL OF NURSING SCHOLARSHIP, 2007, 39 (03) : 214 - 221
  • [6] Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations
    Stroup, TS
    Alves, WM
    Hamer, RM
    Lieberman, JA
    NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (02) : 133 - 146
  • [7] Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials
    Khan, Arif
    Schwartz, Kelly
    Stern, Chelsea
    Redding, Nick
    Kolts, Russell L.
    Brown, Walter A.
    Robinson, Donald S.
    JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (12) : 1828 - 1833
  • [8] Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations
    T. Scott Stroup
    Wayne M. Alves
    Robert M. Hamer
    Jeffrey A. Lieberman
    Nature Reviews Drug Discovery, 2006, 5 : 133 - 146
  • [9] Pooling randomized, controlled, clinical trials of antipsychotic treatments for schizophrenia: Baseline clinical and functional characteristics of patients in randomized clinical trials
    Phillips, GA
    Ascher-Svanum, H
    Marquez, E
    Wade, B
    Gaydos, B
    Dube, S
    Dunayevich, E
    BIOLOGICAL PSYCHIATRY, 2005, 57 (08) : 44S - 44S
  • [10] Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study
    Davis, Sonia M.
    Stroup, T. Scott
    Koch, Gary G.
    Davis, Clarence E.
    Rosenheck, Robert A.
    Lieberman, Jeffrey A.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2011, 3 (02): : 253 - 265
12345